Neuman Thomas G, Banik Riddhi, Karla Surya, Hu Mengyang, Hartin Andrew, Karande Pankaj, Kilduff James, Belfort Georges
Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Sci Adv. 2025 Jun 20;11(25):eadv8656. doi: 10.1126/sciadv.adv8656. Epub 2025 Jun 18.
The increasing clinical trials of single-stranded mRNA (ss-mRNA) therapeutics highlight the urgent need to develop efficient, scalable, and economic purification methods. Current diffusion-driven, resin-based purification techniques constrain productivity and rely on expensive oligo(dT) ligands for target ss-mRNA poly(A) tail hybridization. To overcome these challenges, we use interfacial molecular forces, such as charge and hydrogen bonds, between nucleic acid variants and a positively charged synthetic microporous membrane to purify ss-mRNA, a desirable therapeutic, from an undesirable impurity, immunogenic double-stranded RNA (dsRNA). Membranes achieved high binding capacities (1.28 mg/m) and up to 100% ss-mRNA recovery at ~pH 9.0, with optimized surface density (4000 to 10,000 nmol/m). Purification was operated at rapid flow rates (1.5 ml/min,1000 MV/min) with reusability (>10 trials) and negligible ligand leaching. The key discovery of this cost-effective ligand-less multimodal surface-modified approach is that the addition of the polyamine spermine, which selectively neutralizes dsRNA charge at amine-to-phosphate ratios >450, enhanced separation efficiency.
单链信使核糖核酸(ss - mRNA)疗法的临床试验日益增多,这凸显了开发高效、可扩展且经济的纯化方法的迫切需求。当前基于树脂的扩散驱动纯化技术限制了生产力,并且依赖昂贵的寡聚(dT)配体来实现与目标ss - mRNA聚(A)尾的杂交。为了克服这些挑战,我们利用核酸变体与带正电的合成微孔膜之间的界面分子力(如电荷和氢键),从不良杂质免疫原性双链核糖核酸(dsRNA)中纯化出理想的治疗性物质ss - mRNA。在优化的表面密度(4000至10000 nmol/m²)下,膜在约pH 9.0时实现了高结合容量(1.28 mg/m²)和高达100%的ss - mRNA回收率。纯化过程以快速流速(1.5 ml/min,1000倍体积/分钟)进行,具有可重复使用性(>10次试验)且配体泄漏可忽略不计。这种具有成本效益的无配体多模态表面改性方法的关键发现是,添加多胺精胺可提高分离效率;精胺在胺与磷酸的比例>450时能选择性中和dsRNA电荷。